ReviewCurrent opinion in nephrology and hypertension2012
Shiga toxin-associated hemolytic uremic syndrome: advances in pathogenesis and therapeutics.
Review in Current opinion in nephrology and hypertension, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 38 citations in OpenAlex.
- How We Interpret Thrombosis with Thrombocytopenia Syndrome?International journal of molecular sciences · 2024Review
- A novel Shiga toxin 2a neutralizing antibody therapeutic with low immunogenicity and high efficacy.Antimicrobial agents and chemotherapy · 2024Article
- Integrated Approach for the Diagnosis of Shiga Toxin-Producing Escherichia coli Infections in Humans.Methods in molecular biology (Clifton, N.J.) · 2021Article
- Atypical reduction of plasma ADAMTS13 activity by a non-IgG-type inhibitor in a patient with hemolytic uremic syndrome caused by Shiga toxin-producing Escherichia coli.CEN case reports · 2019Article
- Dynamic Gene Network Analysis of Caco-2 Cell Response to Shiga Toxin-ProducingMicroorganisms · 2019Article
- Shiga toxin triggers endothelial and podocyte injury: the role of complement activation.Pediatric nephrology (Berlin, Germany) · 2019Review
- LPS-primed CD11bScientific reports · 2018Article
- Article
- Article
- Ultrasound findings in EHEC-associated hemolytic-uremic syndrome and their clinical relevance.International urology and nephrology · 2016Article
- [Advances in differential diagnosis and treatment of thrombotic microangiopathy].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2015Article
- Role of bacteriophages in STEC infections: new implications for the design of prophylactic and treatment approaches.F1000Research · 2014Article
- Hemolytic uremic syndrome: toxins, vessels, and inflammation.Frontiers in medicine · 2014Review
- Management of hemolytic-uremic syndrome in children.International journal of nephrology and renovascular disease · 2014Review
- HUS and TTP in Children.Pediatric clinics of North America · 2013Review
- Article
- New insights into Shiga toxin-mediated endothelial dysfunction in hemolytic uremic syndrome.Virulence · 2013Review
- Fatal hemolytic uremic syndrome associated with day care surgery and anaesthesia: a case report.BMC research notes · 2013Article
- Renal and neurological involvement in typical Shiga toxin-associated HUS.Nature reviews. Nephrology · 2012Review
- Familial atypical hemolytic uremic syndrome: a review of its genetic and clinical aspects.Clinical & developmental immunology · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
purpose of reviewDiarrhea-associated hemolytic uremic syndrome (HUS) caused by Shiga toxin-producing Escherichia coli (STEC) continues to be an important public health threat worldwide. Specific therapies are lacking and patient care remains largely supportive. This review discusses the lessons learned from recent events and summarizes key advances made toward understanding the basic mechanisms involved in the pathogenesis of typical HUS. RECENT
findingsThe recent German outbreak of a hybrid organism resulted in an unprecedented number of HUS cases and drastically changed the face of typical (diarrhea-associated) HUS. New findings on the roles of complement and the CXCR4/SDF-1 pathway in HUS pathogenesis are summarized and novel therapeutic strategies are highlighted. SUMMARY: A better understanding of STEC-mediated HUS underlies improved therapeutic approaches. New studies of the mechanistic basis of the disease, together with patient-based studies, have led to key findings with important clinical implications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.